Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: The Company operates a telemedicine platform selling men's wellness products (ED, hair loss, testosterone, weight management) under brands such as Mango, Grow, Mojo, and Slim. It also markets FDA-approved oral testosterone (Prime) and holds patents for respiratory illness prevention technology. The Company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $67,864 | $109,306 |
| Gross Profit | $29,001 | $62,064 |
| Net Loss | $(3,403,141) | $(4,839,489) |
| Loss Per Share (Basic & Diluted) | $(0.22) | $(1.12) |
| Cash and Cash Equivalents | $174,562 | $76,496 |
| Total Assets | $14,449,223 | $16,089,573 |
| Total Liabilities | $974,571 | $890,568 |
| Working Capital | $(525,134) | $656,866 |
| Accumulated Deficit | $(44,050,630) | $(40,647,480) |
Note: Working Capital calculated as Total Current Assets ($212,472) minus Total Current Liabilities ($737,606).
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 38% to $67,864, attributed to a strategic focus on in-house website development and testing of new TRT products prior to a full launch.
- Expense Reduction: Total operating expenses decreased by $1.48 million to $3.16 million. Significant reductions occurred in Investor Relations expenses (down $1.41 million) and Advertising/Marketing (down $187,659).
- Stock-Based Compensation Increase: Stock-based compensation rose to $1.65 million (from $1.05 million) due to stock issuances for employees and consultants in lieu of cash, including a repricing of CEO options.
- Liquidity Deterioration: Cash on hand decreased by $1.31 million to $174,562 due to operating cash outflows with no financing activities in the quarter. The Company moved from a working capital surplus in Q1 2025 to a deficit in Q1 2026.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With an accumulated deficit of $44.1 million and a working capital deficit, management states that current capital resources are insufficient to fund operations for the next 12 months without additional financing.
Outlook: The Company plans to pursue organic growth and strategic acquisitions in the health and wellness space. It intends to launch operations for the "Dermytol" skin brightening brand in Q3 2026. Future funding is expected to come from equity or debt offerings, which may cause significant dilution.
Key Risks:
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00 per share). It has until August 3, 2026, to regain compliance or face delisting.
- Regulatory Scrutiny: Products are compounded under Section 503A of the FFD&C Act and are not FDA-approved. The Company faces risks regarding FDA enforcement actions, potential reclassification as a manufacturer, and telehealth prescribing regulations.
- Litigation: A lawsuit filed by Eli Lilly regarding false advertising of the "TRIM" product was settled for $20,000 in June 2025. The Company is also defending against a FINRA arbitration claim by Boustead Securities for over $1 million in fees and has filed a $73 million lawsuit against a former technology vendor, Clarity Ventures.
Investor Verification Checklist
- Cash Runway: Verify the timeline for raising additional capital given the $174k cash balance and $1.3M quarterly operating cash burn.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before the August 3, 2026 deadline to avoid delisting.
- Related Party Transactions: Review the extent of reliance on Epiq Scripts (CEO-owned pharmacy) for product fulfillment and the terms of the "Clarification Agreement" regarding the CEO's subsidiary equity.
- Regulatory Exposure: Assess the risk of FDA enforcement actions against the Company's compounding model and telehealth practices.
- Dilution Risk: Evaluate the impact of outstanding warrants (2.9M shares) and convertible preferred stock on future equity dilution if financing is raised.